Nautilus Biotechnology, Inc. (NAUT) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Nautilus Biotechnology Reports Second Quarter 2022 Financial Results
August 2, 2022 6:48 AM EDTSEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022.
Recent Highlights
Reported total operating expenses for the second quarter of 2022 of $15.5 million, down sequentially from $16.0 million in the first quarter of 2022 and from $16.8 million in the fourth quarter of 2021.Announced the hiring of industry veterans Eric Spence and Ken Kuhn as VP of Instrument Engineering and VP of Reagent and Process Development,... More